Your browser doesn't support javascript.
loading
Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey.
Carnio, S; Galetta, D; Scotti, V; Cortinovis, D L; Antonuzzo, A; Pisconti, S; Rossi, A; Martelli, O; Cecere, F L; Lunghi, A; Del Conte, A; Montagna, E S; Topulli, J; Pelizzoni, D; Rapetti, S G; Gianetta, M; Pacchiana, M V; Pegoraro, V; Cataldo, N; Bria, E; Novello, S.
Afiliação
  • Carnio S; Thoracic Oncology Unit, San Luigi Hospital, University of Turin, Regione Gonzole 10, Orbassano, Turin, Italy. simona.carnio@libero.it.
  • Galetta D; Clinical Cancer Center "Giovanni Paolo II", Bari, Italy.
  • Scotti V; Department of Oncology Radiation Therapy Unit, Careggi University Hospital, Florence, Italy.
  • Cortinovis DL; Medical Oncology Unit, San Gerardo Hospital, Monza, Italy.
  • Antonuzzo A; Division of Medical Oncology Department of Oncology, S. Chiara University Hospital, Pisa, Italy.
  • Pisconti S; Department of OncoEmatology Medical Oncology, SG Moscati Hospital, Taranto, Italy.
  • Rossi A; Division of Medical Oncology, SG Moscati Hospital, Avellino, Italy.
  • Martelli O; Medical Oncology Unit, San Giovanni Addolorata Hospital, Rome, Italy.
  • Cecere FL; Department of Oncology, Medical Oncology Unit, Careggi University Hospital, Florence, Italy.
  • Lunghi A; Department of Oncology, Medical Oncology Unit, Careggi University Hospital, Florence, Italy.
  • Del Conte A; Department of Medical Oncology, Azienda per l'Assistenza Sanitaria No.5, Friuli Occidentale, Presidio Ospedaliero di Pordenone, Pordenone, Italy.
  • Montagna ES; Clinical Cancer Center "Giovanni Paolo II", Bari, Italy.
  • Topulli J; Department of Oncology Radiation Therapy Unit, Careggi University Hospital, Florence, Italy.
  • Pelizzoni D; Medical Oncology Unit, San Gerardo Hospital, Monza, Italy.
  • Rapetti SG; Thoracic Oncology Unit, San Luigi Hospital, University of Turin, Regione Gonzole 10, Orbassano, Turin, Italy.
  • Gianetta M; Thoracic Oncology Unit, San Luigi Hospital, University of Turin, Regione Gonzole 10, Orbassano, Turin, Italy.
  • Pacchiana MV; Thoracic Oncology Unit, San Luigi Hospital, University of Turin, Regione Gonzole 10, Orbassano, Turin, Italy.
  • Pegoraro V; Quintiles IMS, Milan, Italy.
  • Cataldo N; Quintiles IMS, Milan, Italy.
  • Bria E; Medical Oncology, Department of Medicine, Verona, Italy.
  • Novello S; Thoracic Oncology Unit, San Luigi Hospital, University of Turin, Regione Gonzole 10, Orbassano, Turin, Italy.
Support Care Cancer ; 26(6): 1841-1849, 2018 Jun.
Article em En | MEDLINE | ID: mdl-29270827
ABSTRACT

PURPOSE:

Chemotherapy-induced nausea and vomiting (CINV) still represents a common side-effect of chemotherapy, and often, its perception differs between patients and healthcare professionals. The aim of this study was to evaluate the agreement on the perception of CINV and other items among clinicians, patients, and nurses.

METHODS:

This observational prospective study was part of an evaluation program promoted by the Women Against Lung Cancer in Europe (WALCE) Onlus. From August 2015 to February 2016, a survey was administered in 11 oncologic institutions to 188 stage IV lung cancer patients and to their oncologists and nurses during first-line chemotherapy. Our survey investigated 11 aspects anxiety, mood, weakness, appetite, nausea, vomiting, pain, drowsiness, breath, general condition, and trust in treatments. These items were assessed through Numerical Rating Scale at four consecutive evaluations at T0 (immediately prior to the first cycle), at T1 (immediately prior to the second cycle), at T2 (immediately prior to the third cycle), and at T3 (immediately prior to the fourth cycle). Clinician versus patient (CvP), nurse versus patient (NvP), and clinician versus nurse (CvN) agreements were estimated applying Weighted Cohen's kappa. A multivariate logistic model and generalized equation estimates were applied to evaluate factors possibly influencing CINV development.

RESULTS:

The incidence of patients reporting CINV varied from 40% at T0 to 71% at T3. Both CvP and NvP agreement on the investigated items were mainly moderate, slightly increasing over time, and becoming substantial for some items, in particular for NvP. Pre-chemotherapy anxiety in its mild, moderate, and severe manifestations, as well as mild, moderate, and severe anxiety experienced after chemotherapy start, exposed patients to a higher risk of anticipatory and acute/delayed CINV, respectively.

CONCLUSIONS:

Despite clinical staff awareness of patients' status and perceptions, CINV still represents a clinical problem. This study confirms that particular attention should be paid to anxiety due to its key role in CINV development.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vômito / Neoplasias Pulmonares / Antieméticos / Náusea / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Support Care Cancer Assunto da revista: NEOPLASIAS / SERVICOS DE SAUDE Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vômito / Neoplasias Pulmonares / Antieméticos / Náusea / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Support Care Cancer Assunto da revista: NEOPLASIAS / SERVICOS DE SAUDE Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália